What’s Next for MS Treatment? Key Takeaways from ECTRIMS 2025

What were the biggest developments in multiple sclerosis treatment at ECTRIMS 2025? As the 41st Congress came to a close in Barcelona, attention turned to new clinical trial results and what they could mean for the future of MS care.

Dr. Sharmilee Gnanapavan, Consultant Neurologist at Barts Health and Princess Alexandra Hospital NHS Trust (UK), joins host Brett Drummond to unpack the key treatment takeaways from ECTRIMS 2025, the research worth watching, and what the MS community can look forward to as the Congress heads to Toronto in 2026.

Sponsorship Disclosure: This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.